| Ryan Thomas Gunlikson, MD | |
|
2000 Hospital Way, Whitefish, MT 59937 | |
| (406) 862-5575 | |
| (406) 862-3797 |
| Full Name | Ryan Thomas Gunlikson |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 30 Years |
| Location | 2000 Hospital Way, Whitefish, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053321265 | NPI | - | NPPES |
| 0159171 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 8596 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Valley Hospital | Whitefish, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Logan Health - Whitefish | 9335033687 | 43 |
News Archive
As researchers develop an ever-expanding toolkit of nanoparticles for use as drug and imaging agent delivery vehicles, there is a growing need to understand how a given nanoparticle's physical and chemical properties affect biological activity and toxicity.
Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.
Researchers at Chalmers University of Technology and Gothenburg University in Sweden have achieved something long thought almost impossible - counting the molecules of the neurotransmitter glutamate released when a signal is transferred between two brain cells. With a new analysis method, they showed that the brain regulates its signals using glutamate in more ways than previously realised.
Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.
› Verified 7 days ago
| Entity Name | Logan Health - Whitefish |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396710851 PECOS PAC ID: 9335033687 Enrollment ID: O20040209001144 |
News Archive
As researchers develop an ever-expanding toolkit of nanoparticles for use as drug and imaging agent delivery vehicles, there is a growing need to understand how a given nanoparticle's physical and chemical properties affect biological activity and toxicity.
Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.
Researchers at Chalmers University of Technology and Gothenburg University in Sweden have achieved something long thought almost impossible - counting the molecules of the neurotransmitter glutamate released when a signal is transferred between two brain cells. With a new analysis method, they showed that the brain regulates its signals using glutamate in more ways than previously realised.
Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Thomas Gunlikson, MD Po Box 3031, Kalispell, MT 59903-3031 Ph: (406) 755-2823 | Ryan Thomas Gunlikson, MD 2000 Hospital Way, Whitefish, MT 59937 Ph: (406) 862-5575 |
News Archive
As researchers develop an ever-expanding toolkit of nanoparticles for use as drug and imaging agent delivery vehicles, there is a growing need to understand how a given nanoparticle's physical and chemical properties affect biological activity and toxicity.
Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.
Researchers at Chalmers University of Technology and Gothenburg University in Sweden have achieved something long thought almost impossible - counting the molecules of the neurotransmitter glutamate released when a signal is transferred between two brain cells. With a new analysis method, they showed that the brain regulates its signals using glutamate in more ways than previously realised.
Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.
› Verified 7 days ago
Philip Lee Cardan, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 704c East 13th Street, Suite 220, Whitefish, MT 59937 Phone: 406-755-7050 |